ST-503 will be evaluated in a phase 1/2 trial with the first patient scheduled to receive the therapy in the coming months. The Food and Drug Administration (FDA) has granted Fast Track designation to ...
—This cross-sectional study investigated a possible association between a high GI symptom burden in types 1 and 2 diabetes with the presence of various neuropathies. A high gastrointestinal (GI) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback